ArticleFrontiers in immunology2026
Hospital exemption use of virus-specific T-lymphocytes in children: early experience within the Allovista clinical trial framework.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- General Commentary: From hospital exemption to evidence: a statistical framework for leveraging real-world data.Frontiers in immunology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adoptive transfer of virus-specific T lymphocytes (VST) is an emerging strategy for refractory viral infections in immunocompromised individuals and is being prospectively evaluated in the ALLOVISTA clinical trial. Here we describe our experience with hospital-exemption advanced therapy medicinal product (ATMP-HE) VST in six pediatric transplant recipients. Methods: Six children and adolescents (median age 4.5 years, range 2.5-18.5) treated in two Polish centers received VST for refractory viremia after allogeneic hematopoietic stem cell transplantation: adenovirus (ADV) in three cases, EBV-driven disease (EBV/PTLD or HL relapse with EBV reactivation) in three, including one patient with concomitant CMV/EBV/ADV infection. All patients had failed conventional antiviral and/or immunochemotherapy (cidofovir, rituximab, chemotherapy). VST were generated from allo-HSCT or related donors using automated CliniMACS Prodigy Cytokine Capture System (IFN-γ CCS, Miltenyi Biotec) following antigenic stimulation with viral peptide pools and released as ATMP-HE according to the ALLOVISTA protocol. A single intravenous infusion of 1.01×10 Results: Virological outcomes were evaluable in five patients. Four of five (80%) evaluated patients achieved at least a 1-log reduction in viral load, including two (40%) with complete clearance by week 4 (one EBV, one ADV). Two additional patients had marked but incomplete or transient viral load reductions, one patient showed minimal virological change. Despite biological activity, four children died: from progressive EBV disease (n=1), ADV infection (n=1), relapse of HL (n=1) and multi-organ failure with invasive fungal disease in a child with multi-viral infection (n=1). Two patients with complete virological responses are alive with sustained remission of viremia at the last follow-up. No new-onset or worsening aGVHD was documented after VST infusion. Conclusions: VST administered as an ATMP-HE are feasible in routine clinical practice and demonstrate rapid antiviral activity in heavily pretreated pediatric patients. However, advanced viral disease and competing complications limit overall survival, underscoring the need for earlier intervention and advocating for treatment within the ongoing ALLOVISTA trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.